EWA 401

Drug Profile

EWA 401

Alternative Names: EW-A-401; VEGF ZFP +434; VZ+434-P65; ZFP-Therapeutics; Zinc finger DNA binding protein - Sangamo

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sangamo BioSciences
  • Class Gene therapies; Vascular disorder therapies; Zinc finger DNA binding proteins
  • Mechanism of Action Gene transference; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Intermittent claudication; Ischaemic heart disorders; Peripheral vascular disorders

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 04 Jun 2008 Phase I development is ongoing
  • 21 May 2008 Pharmacodynamics data from a phase I trial in critical limb ischaemia released by Sangamo BioSciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top